Next Reorg

Quote





Sounds like the false bravado of the US SLT should hold out that long. They’ve been out of touch for a few years. Will
Take them some time to accepts the reality that has been all too apparent to everyone else.
 


Reorg is currently in the works. Chapter 3.25 will commence in Q3. The all hands on deck is a ruse for let’s get everyone trained now, while ZS lays out new territories and workloads. All trained on Sema makes it very easy to cut and place individuals. In addition it makes it easier to trim some salary from specialty.
 


Agree nothing will happen in 2025. We are a one hit molecule at this point. Then, cut the fat. DBMS should have 10 reps, get rid of area directors, scale back on RBD, get rid of ASCDs, get rid of PEMS, get rid of educators, obesity call on ob, weightloss, psych, gi and edcs call on endo cards neph.
 














They say sales needs to get Wegovy back on track and Ozempic back to growth. Either way, some of you will lose your jobs. Don’t think for a second your performance will save you when the hammer drops.
 


anonymous said:
They say sales needs to get Wegovy back on track and Ozempic back to growth. Either way, some of you will lose your jobs. Don’t think for a second your performance will save you when the hammer drops.
Click to expand...
Company realizes Lilly gaining share and momentum. The cuts will be based on impact measures rating, especially calls on targets. Timing confirmed and in place. Planning meetings in Plainsboro for RBDs in July after shutdown.
 


anonymous said:
Company realizes Lilly gaining share and momentum. The cuts will be based on impact measures rating, especially calls on targets. Timing confirmed and in place. Planning meetings in Plainsboro for RBDs in July after shutdown.
Click to expand...
Bring it on!! This greedy shit show of a company deserves to sink. Novo launched Wegovy and ran out of product within months. It took them 3 YEARS to have Wegovy supply. I wholeheartedly believe they only have enough supply now because no one is prescribing. Lilly has the superior product. Oh wait , we have CV indication. No one cares. If the patient looses weight their CV risks decline. All of their risks for health issues associated with obesity decrease. Oh wait we sample! Again, obviously no one cares. Bring on a package.
 


anonymous said:
Bring it on!! This greedy shit show of a company deserves to sink. Novo launched Wegovy and ran out of product within months. It took them 3 YEARS to have Wegovy supply. I wholeheartedly believe they only have enough supply now because no one is prescribing. Lilly has the superior product. Oh wait , we have CV indication. No one cares. If the patient looses weight their CV risks decline. All of their risks for health issues associated with obesity decrease. Oh wait we sample! Again, obviously no one cares. Bring on a package.
Click to expand...
What they said!
 


anonymous said:
...The cuts will be based on impact measures rating, especially calls on targets...
Click to expand...
Well then we will be left with a lot of reps who don't actually work in the field a whole lot but get on lots of teams calls. Offices don't even know my partner's name but I'm sure they will survive. That will end well.
 




anonymous said:
Bring it on!! This greedy shit show of a company deserves to sink. Novo launched Wegovy and ran out of product within months. It took them 3 YEARS to have Wegovy supply. I wholeheartedly believe they only have enough supply now because no one is prescribing. Lilly has the superior product. Oh wait , we have CV indication. No one cares. If the patient looses weight their CV risks decline. All of their risks for health issues associated with obesity decrease. Oh wait we sample! Again, obviously no one cares. Bring on a package.
Click to expand...
You sound like a Lilly REP! Its about GLP-1, close to the homology of native GLP1, Not primarily just weight loss. The Surpass-CVOT is set to underwhelm. Mounjaro has a homology to native GLP-1 to about 30-40%, while its GIP is 80%. It's GLP-1 activity is 1/5 of Ozempic's and at best a weak to modest agonist at the receptor site. Ozempic is the most potent GLP-1 ever created. Now we know that ASCVD reduction is more about GLP-1 than Weight loss. Tanzeum's CVOT trial yielded a weight loss of 1.5lbs and had a 22% reduction in 3-point mace. Lilly's CVOT trial is powered to include modest BMI's so weight loss will not be as significant. GIP has been associated with inflammation as well. What we will see is that Mounjaro will fail to achieve noninferiority vs. trulicity in a 4 point mace composite while showing noninferiority to a single component of the 4 point mace being Heart Failure. 4 point MACE was added as a security blanket just in case the overall composite was negative.
 




anonymous said:
You sound like a Lilly REP! It’s about GLP-1, close to the homology of native GLP1, Not primarily just weight loss. The Surpass-CVOT is set to underwhelm. Mounjaro has a homology to native GLP-1 to about 30-40%, while its GIP is 80%. It's GLP-1 activity is 1/5 of Ozempic's and at best a weak to modest agonist at the receptor site. Ozempic is the most potent GLP-1 ever created. Now we know that ASCVD reduction is more about GLP-1 than Weight loss. Tanzeum's CVOT trial yielded a weight loss of 1.5lbs and had a 22% reduction in 3-point mace. Lilly's CVOT trial is powered to include modest BMI's so weight loss will not be as significant. GIP has been associated with inflammation as well. What we will see is that Mounjaro will fail to achieve noninferiority vs. trulicity in a 4 point mace composite while showing noninferiority to a single component of the 4 point mace being Heart Failure. 4 point MACE was added as a security blanket just in case the overall composite was negative.
Click to expand...
Thanks for the science class, respectfully, nobody will give a shit if it’s a weak study.
 



Write your reply...
Top Bottom
Back
Quote